Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma

Annals of Hematology

Volumn 91, Issue 3, 2012, Pages 375-382

  Aoki, Tomohiro ^a   Nishiyama, Takahiro ^a   Imahashi, Nobuhiko ^a   Kitamura, Kunio ^a  

^a Ichinomiya Municipal Hospital   (Japan)

Author keywords

Absolute lymphocyte count; Diffuse large B cell lymphoma; Lymphopenia; Relapse; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; SOLUBLE INTERLEUKIN 2 RECEPTOR; VINCRISTINE;

ABSOLUTE LYMPHOCYTE COUNT; ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL ASSESSMENT; COHORT ANALYSIS; EARLY RELAPSE; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FEMALE; GENDER; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RELAPSE; RETROSPECTIVE STUDY; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MALE; MIDDLE AGED; PREDNISONE; RECURRENCE; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 84857369335     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1305-1     Document Type: Article

References (30)

1. P Feugier A Van Hoof C Sebban P Solal-Celigny R Bouabdallah C Ferme B Christian E Lepage H Tilly F Morschhauser P Gaulard G Salles A Bosly C Gisselbrecht F Reyes B Coiffier 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 18 4117 4126 10.1200/JCO.2005.09.131 15867204 10.1200/JCO.2005.09.131 1:CAS:528: DC%2BD2MXmt1elsr0%3D (Pubitemid 46211317)
2. M Pfreundschuh L Trumper A Osterborg R Pettengell M Trneny K Imrie D Ma D Gill J Walewski PL Zinzani R Stahel S Kvaloy O Shpilberg U Jaeger M Hansen T Lehtinen A Lopez-Guillermo C Corrado A Scheliga N Milpied M Mendila M Rashford E Kuhnt M Loeffler 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 5 379 391 10.1016/S1470-2045(06)70664-7 16648042 10.1016/S1470-2045(06)70664-7 1:CAS:528:DC%2BD28XjvFWlsbw%3D
3. E Vellenga WL van Putten MB van't Veer JM Zijlstra WE Fibbe MH van Oers LF Verdonck PW Wijermans GW van Imhoff PJ Lugtenburg PC Huijgens 2008 Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Blood 111 2 537 543 10.1182/blood-2007-08-108415 17971487 10.1182/blood-2007-08-108415 1:CAS:528:DC%2BD1cXns1CgsA%3D%3D
4. T Philip C Guglielmi A Hagenbeek R Somers H Van der Lelie D Bron P Sonneveld C Gisselbrecht JY Cahn JL Harousseau, et al. 1995 Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 23 1540 1545 10.1056/NEJM199512073332305 7477169 10.1056/NEJM199512073332305 1:STN:280:DyaK28%2FmslCgtQ%3D%3D
5. C Gisselbrecht B Glass N Mounier D Singh Gill DC Linch M Trneny A Bosly N Ketterer O Shpilberg H Hagberg D Ma J Briere CH Moskowitz N Schmitz 2010 Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era J Clin Oncol 28 27 4184 4190 10.1200/JCO.2010.28. 1618 20660832 10.1200/JCO.2010.28.1618
6. JC Weeks BY Yeap GP Canellos MA Shipp 1991 Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission J Clin Oncol 9 7 1196 1203 1710656 1:STN:280:DyaK3M3lvFWksg%3D%3D
7. EC Vonderheid Q Zhang SR Lessin M Polansky JT Abrams RD Bigler MA Wasik 1998 Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma J Am Acad Dermatol 38 2 Pt 1 207 220 9486676 10.1016/S0190-9622(98)70597-3 1:STN:280:DyaK1c7ks1Srsw%3D%3D (Pubitemid 28100835)
8. LF Porrata K Rsitow DJ Inwards SM Ansell IN Micallef PB Johnston TM Habermann TE Witzig JP Colgan GS Nowakowski CA Thompson SN Markovic 2010 Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma Leukemia 24 7 1343 1349 10.1038/leu.2010.108 20485372 10.1038/leu.2010.108 1:CAS:528:DC%2BC3cXovFKms7k%3D
9. D Behl K Ristow SN Markovic TE Witzig TM Habermann JP Colgan DJ Inwards WL White SM Ansell IN Micallef PB Johnston LF Porrata 2007 Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas Br J Haematol 137 5 409 415 10.1111/j.1365-2141.2007.06596.x 17433025 10.1111/j.1365-2141.2007.06596.x 1:CAS:528:DC%2BD2sXotVOgsr0%3D (Pubitemid 46698290)
10. MC Cox I Nofroni G Laverde A Ferrari R Amodeo C Tatarelli F Saltarelli B Veggia MA Aloe-Spiriti L Ruco B Monarca 2008 Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma Br J Haematol 141 2 265 268 10.1111/j.1365-2141.2008.07028.x 18353165 10.1111/j.1365-2141.2008.07028.x (Pubitemid 351406210)
11. Y Oki K Yamamoto H Kato Y Kuwatsuka H Taji Y Kagami Y Morishima 2008 Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab Eur J Haematol 81 6 448 453 10.1111/j.1600-0609.2008.01129.x 18691256 10.1111/j.1600-0609.2008.01129.x
12. D Talaulikar A Choudhury B Shadbolt M Brown 2008 Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas Leuk Lymphoma 49 5 959 964 10.1080/10428190801959026 18464115 10.1080/10428190801959026 1:CAS:528:DC%2BD1cXnsFaru7o%3D (Pubitemid 351942751)
13. I Ray-Coquard C Cropet M Van Glabbeke C Sebban A Le Cesne I Judson O Tredan J Verweij P Biron I Labidi JP Guastalla T Bachelot D Perol S Chabaud PC Hogendoorn P Cassier A Dufresne JY Blay 2009 Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas Cancer Res 69 13 5383 5391 10.1158/0008-5472.CAN-08-3845 19549917 10.1158/0008-5472.CAN-08- 3845 1:CAS:528:DC%2BD1MXnvFWqu7c%3D
14. BD Cheson B Pfistner ME Juweid RD Gascoyne L Specht SJ Horning B Coiffier RI Fisher A Hagenbeek E Zucca ST Rosen S Stroobants TA Lister RT Hoppe M Dreyling K Tobinai JM Vose JM Connors M Federico V Diehl 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 5 579 586 10.1200/JCO.2006.09. 2403 17242396 10.1200/JCO.2006.09.2403 (Pubitemid 350002966)
15. H Goto H Tsurumi M Takemura Y Ino-Shimomura S Kasahara M Sawada T Yamada T Hara K Fukuno N Goto M Okuno T Takami M Seishima H Moriwaki 2005 Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index J Cancer Res Clin Oncol 131 2 73 79 10.1007/s00432-004-0600-9 15503137 10.1007/s00432-004-0600-9 1:CAS:528:DC%2BD2MXntF2ltA%3D%3D (Pubitemid 40192931)
16. DH Kim JH Baek YS Chae YK Kim HJ Kim YH Park HS Song JS Chung MS Hyun SK Sohn 2007 Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma Leukemia 21 10 2227 2230 10.1038/sj.leu.2404780 17554383 10.1038/sj.leu.2404780 1:CAS:528: DC%2BD2sXhtVGmsb%2FJ (Pubitemid 47423827)
17. Y Oki H Kato K Matsuo Y Kuwatsuka H Taji K Yamamoto Y Kagami Y Morishima 2008 Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy Leuk Lymphoma 49 7 1345 1351 10.1080/10428190802108888 18452099 10.1080/10428190802108888 1:CAS:528:DC%2BD1cXot1Klsbk%3D (Pubitemid 352015798)
18. N Niitsu K Iijima A Chizuka 2001 A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma Eur J Haematol 66 1 24 30 11168504 10.1034/j.1600-0609.2001.00334.x 1:STN:280:DC%2BD3M7hvFKmsg%3D%3D (Pubitemid 32099406)
19. T Morito M Fujihara H Asaoku A Tari Y Sato K Ichimura T Tanaka K Takata M Tamura T Yoshino 2009 Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma Cancer Sci 100 7 1255 1260 10.1111/j.1349-7006.2009.01167.x 19432905 10.1111/j.1349-7006.2009.01167.x 1:CAS:528:DC%2BD1MXosl2ktb0%3D
20. H Tilly M Dreyling 2009 Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl 4 110 112 10.1093/annonc/mdp145 19454426
21. J Phan A Mazloom L Jeffrey Medeiros TG Zreik C Wogan F Shihadeh MA Rodriguez L Fayad N Fowler V Reed P Horace BS Dabaja 2010 Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy J Clin Oncol 28 27 4170 4176 10.1200/JCO.2009.27.3441 20713859 10.1200/JCO.2009.27.3441
22. A Plonquet C Haioun JP Jais AL Debard G Salles MC Bene P Feugier C Rabian O Casasnovas M Labalette E Kuhlein JP Farcet JF Emile C Gisselbrecht MH Delfau-Larue 2007 Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma Ann Oncol 18 7 1209 1215 10.1093/annonc/mdm110 17496307 10.1093/annonc/mdm110 1:STN:280:DC%2BD2svls1Cksw%3D%3D (Pubitemid 47244368)
23. MC Cox I Nofroni L Ruco R Amodeo A Ferrari G La Verde P Cardelli E Montefusco E Conte B Monarca MA Aloe-Spiriti 2008 Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma Leuk Lymphoma 49 9 1745 1751 10.1080/10428190802226425 18798109 10.1080/10428190802226425
24. S Strand WJ Hofmann H Hug M Muller G Otto D Strand SM Mariani W Stremmel PH Krammer PR Galle 1996 Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 2 12 1361 1366 8946836 10.1038/nm1296-1361 1:CAS:528:DyaK28Xntlyls7g%3D (Pubitemid 26401740)
25. M Tanaka T Suda K Haze N Nakamura K Sato F Kimura K Motoyoshi M Mizuki S Tagawa S Ohga K Hatake AH Drummond S Nagata 1996 Fas ligand in human serum Nat Med 2 3 317 322 8612231 10.1038/nm0396-317 1:CAS:528:DyaK28XhsVGkt7o%3D (Pubitemid 26080652)
26. T Saito I Kuss G Dworacki W Gooding JT Johnson TL Whiteside 1999 Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer Clin Cancer Res 5 6 1263 1273 10389908 1:STN:280:DyaK1Mzhs1Oksg%3D%3D (Pubitemid 29282928)
27. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams MR Heyman I Bence-Bruckler CA White F Cabanillas V Jain AD Ho J Lister K Wey D Shen BK Dallaire 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 8 2825 2833 9704735 1:CAS:528:DyaK1cXlsFCgu7c%3D (Pubitemid 28363048)
28. K Tobinai 2002 Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan Int J Hematol 76 5 411 419 12512835 10.1007/BF02982806 1:CAS:528: DC%2BD3sXlt1artQ%3D%3D
29. K Stamatopoulos T Papadaki C Pontikoglou I Athanasiadou N Stavroyianni J Bux I Batsis K Pyrovolaki G Paterakis D Anagnostou A Anagnostopoulos HA Papadaki 2008 Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia Leukemia 22 7 1446 1449 10.1038/sj.leu.2405077 18185527 10.1038/sj.leu.2405077 1:CAS:528:DC%2BD1cXosFSnu7g%3D (Pubitemid 352006092)
30. MS Czuczman AJ Grillo-Lopez CA White M Saleh L Gordon AF LoBuglio C Jonas D Klippenstein B Dallaire C Varns 1999 Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 17 1 268 276 10458242 1:CAS:528: DyaK1MXltVyrsA%3D%3D (Pubitemid 29022402)